IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by State Street Corp

State Street Corp decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,613,360 shares of the company's stock after selling 12,910 shares during the quarter. State Street Corp owned approximately 4.41% of IDEXX Laboratories worth $1,825,543,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in IDXX. Chicago Partners Investment Group LLC raised its holdings in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock valued at $340,000 after acquiring an additional 96 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of IDEXX Laboratories by 13.8% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after purchasing an additional 1,453 shares during the period. National Pension Service boosted its stake in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company's stock valued at $93,957,000 after purchasing an additional 12,647 shares in the last quarter. EFG Asset Management Americas Corp. boosted its stake in shares of IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock valued at $6,201,000 after purchasing an additional 3,966 shares in the last quarter. Finally, Larson Financial Group LLC increased its holdings in IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after buying an additional 2,241 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on IDXX shares. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. dropped their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 target price for the company. Barclays lowered their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Finally, StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $546.56.

IDEXX Laboratories Stock Performance

IDXX stock traded up $8.20 during midday trading on Friday, reaching $435.69. The stock had a trading volume of 551,918 shares, compared to its average volume of 649,999. The firm has a fifty day simple moving average of $444.47 and a two-hundred day simple moving average of $474.16. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. The stock has a market cap of $35.68 billion, a PE ratio of 42.01, a P/E/G ratio of 3.97 and a beta of 1.37.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the business posted $2.53 earnings per share. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company's stock, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.11% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.